002550 千红制药
2024/09 - 九个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)12.5627.41514.1308.608-5.980
总资产报酬率 ROA (%)11.2006.52812.1717.301-4.902
投入资产回报率 ROIC (%)12.3207.13813.4548.285-6.079

边际利润分析
销售毛利率 (%)54.01843.26538.59144.46247.613
营业利润率 (%)28.73211.26415.62811.165-9.880
息税前利润/营业总收入 (%)28.68810.86612.42211.465-8.894
净利润/营业总收入 (%)24.7269.84813.8889.939-8.853

收益指标分析
经营活动净收益/利润总额(%)71.94872.82986.68070.290-116.592
价值变动净收益/利润总额(%)1.8514.312-1.2730.306-9.480
营业外收支净额/利润总额(%)0.209-0.4090.0900.0192.578

偿债能力分析
流动比率 (X)8.3227.9006.0655.2985.351
速动比率 (X)6.2104.9754.1363.9464.265
资产负债率 (%)10.04110.56313.27615.55715.758
带息债务/全部投入资本 (%)-2.614-0.6541.0240.704--
股东权益/带息债务 (%)-3,784.785-14,863.1289,308.95713,501.109-5,052.999
股东权益/负债合计 (%)891.910840.232657.760545.117538.367
利息保障倍数 (X)-274.217-30.840-3.85738.525-7.131

营运能力分析
应收账款周转天数 (天)55.42978.39075.07875.3320.000
存货周转天数 (天)241.364199.089119.244123.8710.000